Weijia Fang
- Oncology top 1%
- Molecular Biology top 10%
- Hepatology top 1%
- Pulmonary and Respiratory Medicine top 5%
- Immunology top 5%
- Co-authors
- Shuiguang DengHailiang ZhaoJianwei YinSchahram DustdarAlbert Y. ZomayaPeng ZhaoYi ZhengHangyu Zhang
- Topics
- Cancer Immunotherapy and Biomarkers (40 papers)Colorectal Cancer Treatments and Studies (27 papers)Pancreatic and Hepatic Oncology Research (17 papers)
- Cited by
- HepatologyOncologyCancer Research
- Journals
- CellJournal of Clinical OncologySHILAP Revista de lepidopterología
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Weijia Fang
130 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Oncology 1.7k
- Molecular Biology 1.1k
- Hepatology 748
- Pulmonary and Respiratory Medicine 715
- Immunology 592
Countries citing papers authored by Weijia Fang
This map shows the geographic impact of Weijia Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijia Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijia Fang more than expected).
Fields of papers citing papers by Weijia Fang
This network shows the impact of papers produced by Weijia Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijia Fang. The network helps show where Weijia Fang may publish in the future.
Co-authorship network of co-authors of Weijia Fang
This figure shows the co-authorship network connecting the top 25 collaborators of Weijia Fang. A scholar is included among the top collaborators of Weijia Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weijia Fang. Weijia Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 35 | |
| 3 | 10 | |
| 4 | 5 | |
| 5 | 8 | |
| 6 | Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironmentbreakdown → | 68 |
| 7 | 3 | |
| 8 | 4 | |
| 9 | 46 | |
| 10 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trialbreakdown → | 127 |
| 11 | 8 | |
| 12 | 58 | |
| 13 | 7 | |
| 14 | 6 | |
| 15 | 10 | |
| 16 | 36 | |
| 17 | Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligencebreakdown → | 655 |
| 18 | 99 | |
| 19 | Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinomabreakdown → | 392 |
| 20 | 21 |
About Weijia Fang
Weijia Fang is a scholar working on Oncology, Hepatology and Immunology, having authored 139 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (40 papers), Colorectal Cancer Treatments and Studies (27 papers) and Pancreatic and Hepatic Oncology Research (17 papers). The work is most often cited by research in Hepatology (748 citations), Oncology (1.7k citations) and Cancer Research (472 citations). Weijia Fang has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Shuiguang Deng, Hailiang Zhao, Jianwei Yin, Schahram Dustdar, Albert Y. Zomaya, Peng Zhao, Yi Zheng, Hangyu Zhang, Weiqin Jiang and Zhou Tong. Their work appears in journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.